

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1 – 21. (Canceled)

22. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and:

- a) a pharmaceutically effective amount of metformin, or a pharmaceutically acceptable salt thereof; and
- b) a pharmaceutically effective amount of a PTPase inhibiting compound of Claim 1, or a pharmaceutically acceptable salt form thereof; and
- c) optionally, a pharmaceutically effective amount of a sulfonylurea agent.

23. (Previously Presented) The pharmaceutical composition of Claim 22 comprising a pharmaceutically acceptable carrier or excipient and:

- a) a pharmaceutically effective amount of metformin, or a pharmaceutically acceptable salt thereof; and
- b) a pharmaceutically effective amount of (2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-*b*]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid, or (R)-2-[2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-*b*]thiophen-4-yl)-phenoxy]3-phenyl-propionic acid, or (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-*b*]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid, or a pharmaceutically acceptable salt form thereof; and
- c) optionally, a pharmaceutically effective amount of a sulfonylurea agent selected from the group of glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or a pharmaceutically acceptable salt form thereof.